BS, Biology, Trinity College Hartford, Connecticut, 1982

PhD Pharmacology, UNC Chapel Hill, Chapel Hill, North Carolina, 1991

Postdoctoral, Cell Adhesion-Mediated Signaling, UNC Chapel Hill Chapel Hill, North Carolina

Harden, T.K., Petch, L.A., Traynelis, S.F., and Waldo, G.L.  Agonist induced alteration in the membrane form of muscarinic cholinergic receptors.  J. Biol. Chem. 260:13060-13066, 1985.

Silva, C.M., Tully, D.B., Petch, L.A., Jewell, C.M., and Cidlowski, J.A.  Application of a protein blotting procedure to the study of human glucocorticoid receptor interactions with DNA.  Proc. Natl. Acad. Sci. USA  84:1744-1748, 1987.

Earp, H.S., Hepler, J.R., Petch, L.A., Miller, A., Berry, A.R., Raymond, V.W., McCune, B.K., Lee, L.W., Grisham, J.W., and Harden, T.K.  Epidermal growth factor (EGF) and hormones stimulate phosphoinositide hydrolysis and increase EGF-receptor protein synthesis and mRNA levels in rat liver epithelial cells: Evidence for protein kinase C-dependent and independent pathways.  J. Biol. Chem.  263:13868-13874, 1988.

Petch, L.A., Harris, J., Raymond, V.W., Blasband, A., Lee, D.C., and Earp, H.S.  A truncated, secreted form of the epidermal growth factor receptor is encoded by an alternatively spliced transcript in normal rat tissue.  Mol. Cell. Biol.  10:2973-2982, 1990.

Earp, S., Huckle, W., Raymond, V., Petch, L., Marts, S., Bishop, W., and McCune B.  The epidermal growth factor receptor: control of synthesis and signaling function. In Growth Factors and Reproduction, David W. Schomberg ed., Springer-Verlag, pp. 3-22, 1991.

Petch, L.A., Bishop, W., Lee, D.C., and Earp, H.S. Truncated forms of the rat epidermal growth factor receptor. In: Mechanisms of Hepatic Endocytosis. Zuckschwerdt Publishers, San Francisco, 27 pgs.

Lee, D.C., Luetteke, N.C., and Petch, L.A. Transforming growth factor-a and its role in neoplastic progression. In: Oncogenes and Tumor Suppressor Genes in Human Malignancy, Benz,C. and Liu, E., eds., Kluwer Academic Publishers, Boston, 35 pgs.

Burridge, K., Petch, L.A., and Romer, L.H. Signals from Focal Adhesions. Curr. Biol. 2: 537-539, 1992.

Petch, L.A., Bockholt, S., Bouton, A., Parsons, J.T., and Burridge, K.B. Adhesion-induced tyrosine phosphorylation of the p130 src substrate.  J. Cell Sci. 108: 1371-1379, 1995.

Kinch, M.K., Petch, L., Zhong, C., and Burridge, K.  E-Cadherin engagement stimulates tyrosine phosphorylation. Cell Adh. Commun. 4: 425-43, 1997.

Arthur, W.T., Petch, L.A., and  Burridge, K.  Integrin engagement suppresses Rho-A activity via a c-Src-dependent mechanism. Curr. Biol. 10(12): 719-22, 2000.

Schoenwaelder, S.M., Petch, L.A., Williamson, D., Shen, R., Feng, G-S., and Burridge, K.  The Protein-Tyrosine Phosphatase Shp-2 Regulates RhoA activity. Curr. Biol. 10(23): 1523-6, 2000.

Reddy Y.S., Gotzkowsky S.K., Eron J.J., Kim J.Y., Fiske W.D., Fiscus S.A., Petch L., Cohen M.S., and Kashuba A.D.  Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis.  186(9): 1339-43, 2002.

Min S.S., Corbett A.H., Rezk N., Cu-Uvin S., Fiscus S.A., Petch L., Cohen M.S., and Kashuba A.D. Protease Inhibitor and Non-nucleoside Reverse Transcriptase Inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr.  15: 1577-1580, 2004.

L.A. Petch, Hoffman, I.F., Jere C.S., Kazembe P.N., Martinson F.E., D.Chilongozi, Fiscus  S.A. and Cohen M.S. Genotypic Analysis of the Protease and Reverse Transcriptase of HIV-1 Subtype C Isolates from Antiretroviral Drug-Naïve Adults in Malawi. AIDS Res and Hum Retroviruses. 21(9): 57-63, 2005.

Fiscus S.A., Kovacs A., Petch L.A., Hu C., Wiznia A.A., Mofenson LM, Yogev R, McIntosh K, Pelton SI, Napravnik S, Stanley K, and Nachman SA. Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS Res Ther. 4 (2), 2007

Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, and Gulick RM, for the AIDS Clinical Trials Group Protocol 359 Team. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clin Trials 8 (2): 63-7, 2007.

Eron, J.J., Bosch R. J., Bettendorf D., Petch L., Fiscus S. and Frank I.for the AACTG 307 Protocol Team. The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine.  JAIDS  45 (2): 249-251, 2007.

Anderson, J.A., Jiang H., Ding X., Petch L., Journigan T., Fiscus S.A., Haubrich R., Katzenstein D., Gulick R.M. and Swanstrom R. for the ACTG 359 Protocol Team. Genotypic susceptibility scores and HIV-RNA responses in treatment experienced subjects with HIV-1 infection. AIDS Res and Hum Retroviruses. 24(5):685-94, 2008